Patents Assigned to Karuna Therapeutics, Inc.
  • Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
    Patent number: 11890378
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: February 6, 2024
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • Xanomeline derivatives and methods for treating neurological disorders
    Patent number: 11534434
    Abstract: Provided herein are compounds comprising compounds of formula I and/or salts thereof; wherein at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 is fluorine, and the remainder are independently chosen from hydrogen and fluorine; and R14, R15, R16, R17, R18, R19, R20, R21, R22, and R23 are independently chosen from hydrogen and deuterium; with the proviso that when R1, R2, and R3 are fluorine, then at least one of R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 is fluorine or at least one of R14, R15, R16, R17, R18, R19, R20, R21, R22, and R23 is deuterium. Also provided are medicaments comprising these compounds and methods for treating central nervous system disorders with the compounds and medicaments described herein.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: December 27, 2022
    Assignee: Karuna Therapeutics, Inc.
    Inventors: James A. Monn, Clifford Adam Schlecht, Dennis A. Bennett, Giorgio Attardo
  • Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
    Patent number: 11471413
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: October 18, 2022
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
    Patent number: 11452692
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: February 3, 2022
    Date of Patent: September 27, 2022
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
    Patent number: 10933020
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof, and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: March 2, 2021
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation
    Patent number: 10925832
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: February 23, 2021
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert